Skip to main content
SpringerLink
Log in
Book cover

Sjögren’s Syndrome pp 501–514Cite as

Primary Sjögren Syndrome in Primary Health Care

  • Chapter
  • First Online:

  • 1204 Accesses

Abstract

Sjogren’s syndrome (SjS) is a slowly progressive autoimmune disease that predominantly affects middle-aged women, with a female to male ratio on the order of 9:1. SS is characterized by lymphocytic infiltration of the exocrine glands, mainly the lacrimal and salivary glands, resulting in reduced secretory function and oral and ocular dryness. The syndrome can present alone as primary SjS (pSjS) or in the context of underlying connective tissue disease as secondary SjS (sSjS). Although the pathogenesis of the disease remains elusive, environmental, genetic and hormonal factors all appear to contribute [1].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmunity Reviews 2010;9:A305–A310.

    Article  PubMed  Google Scholar 

  2. Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain. Clinical and immunologic expression in 1010 patients. Medicine. 2008;87:210–9.

    Article  PubMed  CAS  Google Scholar 

  3. Lawn JE, Rohde J, Rifkin S, et al. Alma-Ata 30 years on: revolutionary, relevant, and time to revitalise. Lancet. 2008;372(9642):917–27.

    Article  PubMed  Google Scholar 

  4. Sisó A, Aymamí A, Campoy A, et al. Síndrome de Sjögren primario: ?Una entidad infradiagnosticada por el Médico de Familia? 18º Congreso Nacional de la Sociedad Española de Medicina Familiar y Comunitaria. Zaragoza 1998. Aten Primaria. 1998;22 Suppl 1:390.

    Google Scholar 

  5. Allen J, Gay B, Crebolder H et al. The European definitions of general practice/family medicine. The key features of the discipline of general practice. EURACT 2005 (2005). Available in http://www.euract.org/index.php?folder_id=25 Accessed Date: [11-October-2010].

  6. Kassan SjS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004;164:1275–84.

    Article  PubMed  Google Scholar 

  7. Sorlí JV, Doménech IE, Zurián FJ, et al. Sjögren syndrome. Aten Primaria. 2009;41(7):417–9.

    Article  PubMed  Google Scholar 

  8. Fox RI. Sjogren’s syndrome. Lancet. 2005;366:321–31.

    Article  PubMed  CAS  Google Scholar 

  9. Al-Hashimi I. The management of Sjogren’s syndrome in dental practice. J Am Dent Assoc. 2001;132:1409–17.

    PubMed  CAS  Google Scholar 

  10. Caffery B, Simpson TL, Wang S, et al. Rose bengal staining of the temporal conjunctiva differentiates Sjögren’s syndrome from keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2010;51(5):2381–7.

    Article  PubMed  Google Scholar 

  11. García-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine. 2002;81:270–80.

    Article  PubMed  Google Scholar 

  12. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren’s syndrome. Semin Arthritis Rheum. 2000;29:296–304.

    Article  PubMed  CAS  Google Scholar 

  13. Fox PC, Bowman SJ, Segal B, et al. Oral involvement in primary Sjögren syndrome. J Am Dent Assoc. 2008;139:1592–601.

    PubMed  Google Scholar 

  14. Belenguer R, Ramos-Casals M, Brito-Zeron P, et al. Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2005;23:351–6.

    PubMed  CAS  Google Scholar 

  15. Ostuni P, Botsios C, Sfriso P, et al. Prevalence and clinical features of fibromyalgia in systemic lupus erythematosus, systemic sclerosis, and Sjögren’s syndrome. Minerva Med. 2002;93:203–9.

    PubMed  CAS  Google Scholar 

  16. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjogren’s syndrome. Results of a prospective concerted action supported by the European community. Arthritis Rheum. 1993;36:340–7.

    Article  PubMed  CAS  Google Scholar 

  17. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.

    Article  PubMed  CAS  Google Scholar 

  18. Ramos-Casals M, Brito-Zerón P, Pérez-de-Lis M, et al. Sjögren syndrome or Sjögren disease? the histological and immunological bias caused by the 2002 criteria. Clin Rev Allergy Immunol. 2010;38(2–3):178–85.

    Article  PubMed  Google Scholar 

  19. Rosas J, Ramos-Casals M, Ena J, et al. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjogren’s syndrome. Correlation with clinical, immunological and histological features. Rheumatology. 2002;41:670–5.

    Article  PubMed  CAS  Google Scholar 

  20. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262–9.

    Article  PubMed  Google Scholar 

  21. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum. 2002;46:741–7.

    Article  PubMed  Google Scholar 

  22. Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, Ruano M, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2005;44:89–94.

    Article  CAS  Google Scholar 

  23. Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary Sjogren syndrome: hematologic patterns of disease expression. Medicine. 2002;81:281–92.

    Article  PubMed  Google Scholar 

  24. Brito-Zeron P, Ramos-Casals M, Nardi N, et al. Circulating monoclonal immunoglobulins in Sjogren syndrome: prevalence and clinical significance in 237 patients. Medicine. 2005;84:90–7.

    Article  PubMed  CAS  Google Scholar 

  25. Pérez-de-Lis M, Akasbi M, Sisó A, et al. Cardiovascular risk factors in primary Sjögren’s syndrome: a case-control study in 624 patients. Lupus. 2010;19(8):941–8.

    Article  PubMed  Google Scholar 

  26. Kang JH, Lin HC. Comorbidities in patients with primary Sjögren’s Syndrome: a registry-based case-control study. J Rheumatol. 2010;37:1188–94.

    Article  PubMed  Google Scholar 

  27. Segal B, Bowman SJ, Fox PC, et al. Primary Sjögren’s Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009;7:46.

    Article  PubMed  Google Scholar 

  28. Meijer JM, Meiners PM, Huddleston Slater JJ, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology. 2009;48(9):1077–82.

    Article  PubMed  Google Scholar 

  29. Aragona P, Di Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren’s syndrome patients. Br J Ophthalmol. 2002;86(8):879–84.

    Article  PubMed  CAS  Google Scholar 

  30. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86(2):181–4.

    Article  PubMed  Google Scholar 

  31. Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol. 2005;243(6):531–8.

    Article  PubMed  CAS  Google Scholar 

  32. Condon PI, McEwen CG, Wright M, Mackintosh G, Prescott RJ, McDonald C. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol. 1999;83(10):1121–4.

    Article  PubMed  CAS  Google Scholar 

  33. McDonald CC, Kaye SB, Figueiredo FC, Macintosh G, Lockett C. A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond). 2002;16(5):601–7.

    Article  CAS  Google Scholar 

  34. Toda I, Shinozaki N, Tsubota K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren’s syndrome. Cornea. 1996;15(2):120–8.

    Article  PubMed  CAS  Google Scholar 

  35. Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in Sjögren’s syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol. 2004;10(4):169–77.

    Article  PubMed  Google Scholar 

  36. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999;159(2):174–81.

    Article  PubMed  CAS  Google Scholar 

  37. Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren’s syndrome in Taiwan – a double-blind, placebo-controlled trial. J Formos Med Assoc. 2006;105(10):796–803.

    Article  PubMed  CAS  Google Scholar 

  38. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med. 2002;162(11):1293–300.

    Article  PubMed  CAS  Google Scholar 

  39. Leung KC, McMillan AS, Wong MC, Leung WK, Mok MY, Lau CS. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren’s syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol. 2008;27(4):429–36.

    Article  PubMed  CAS  Google Scholar 

  40. Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138(1):6–17.

    Article  PubMed  CAS  Google Scholar 

  41. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46(3):748–54.

    Article  PubMed  CAS  Google Scholar 

  42. Voulgarelis M, Moutsopoulos HM. Malignant lymphoma in primary Sjögren’s syndrome. Isr Med Assoc J. 2001;3:761–6.

    PubMed  CAS  Google Scholar 

  43. Kruszka P, O’Brian RJ. Diagnosis and management of Sjögren syndrome. Am Fam Physician. 2009;79(6):465–70.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Group on Primary Care, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CAP Les Corts, GesClínic, University of Barcelona, Barcelona, Spain

    Antoni Sisó-Almirall & Jaume Benavent

  2. Department of Internal Medicine, ICMiD, Hospital Clínic, Barcelona, Spain

    Xavier Bosch

  3. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain

    Albert Bové & Manuel Ramos-Casals

Authors
  1. Antoni Sisó-Almirall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaume Benavent
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xavier Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albert Bové
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manuel Ramos-Casals
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Barcelona, Surgey, Hospital Clinic, Calle Villarroel, 170, Barcelona, 08036, Spain

    Manuel Ramos-Casals

  2. Massachusetts General Hospital, Boston, 02114, Massachusetts, USA

    John H. Stone

  3. National University of Athens, Athens, Greece

    Haralampos M. Moutsopoulos

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Sisó-Almirall, A., Benavent, J., Bosch, X., Bové, A., Ramos-Casals, M. (2011). Primary Sjögren Syndrome in Primary Health Care. In: Ramos-Casals, M., Stone, J., Moutsopoulos, H. (eds) Sjögren’s Syndrome. Springer, London. https://doi.org/10.1007/978-0-85729-947-5_35

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-947-5_35

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-946-8

  • Online ISBN: 978-0-85729-947-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation